Cardiologs Announces Poster Presentation at ACC 2022
New clinical data shows Cardiologs’ deep learning model can predict the short-term risk of atrial fibrillation (AFib) based on 24-hour Holter recordings that show normal sinus rhythm
PARIS and Boston, Mass. – March 31, 2022 – Cardiologs today announced a poster presentation at the 2022 American College of Cardiology (ACC) meeting in Washington, DC, from April 2-4, 2022.
The poster entitled “Short term prediction of Atrial Fibrillation from ambulatory ECG using deep learning” presents results of a clinical study demonstrating that Cardiologs’ AI algorithm can predict the short-term risk of atrial fibrillation (AFib) based on single-lead Ambulatory electrocardiograms (ECGs) that show normal sinus rhythm.
Previous studies have assessed the long-term possibility for future AFib using AI-based prediction algorithms based on a normal 12-lead ECGs. This study shows Cardiologs’ deep neural network can reliably predict whether AFib will occur in the near future (i.e. within 6 to 14 days) with an area under the curve of 0.79, a ten-point improvement over a basic age and sex-based model.
“In most countries, the short-term Holter is the first ambulatory arrhythmia diagnostic test and, too often, the last. By bringing predictive AFib capabilities to the Holter test, we are empowering cardiologists to pursue the search for AFib without changing the care pathway at all. Cardiologs’ AI can predict the presence of AFib, even when there are no visible signs in the ECG recordings. The algorithm can detect subtle symptoms that suggest future onset, giving much more value to the Holter and helping physicians determine which patients may benefit from long-term monitoring.” said Cardiologs CEO and Co-Founder Yann Fleureau.
AFib remains the most common sustained cardiac arrhythmia, affecting 46 million individuals worldwide. Identifying patients with AFib is a growing priority given the high association with stroke and heart failure, but symptoms often come and go – making the condition challenging to catch. Though convenient, short Holter recordings (24-48 hours) commonly used to confirm suspected AFib have a low detection rate and cannot predict future occurrences.
For more information on the Cardiologs’ platform, visit: www.cardiologs.com
Cardiologs is a medical technology company committed to transforming cardiac diagnostics using medical-grade artificial intelligence and cloud technology. Developed in partnership with leading physicians, the Cardiologs Holter Platform empowers clinicians worldwide to deliver expert cardiac care faster and more efficiently. CE-Marked and FDA cleared for detection of 14 cardiac arrhythmias, the Cardiologs Holter Platform is built on a growing database of more than 20 million ECG recordings and is supported by a number of clinical publications. In November 2021, Cardiologs announced that they were being acquired by Philips to expand their cardiac portfolio.